Oncternal sells assets for up to $68m and calls it quits
American oncology company Oncternal Therapeutics is to wind down operations after announcing the sale of its main drug programmes. Delaware-based…
American oncology company Oncternal Therapeutics is to wind down operations after announcing the sale of its main drug programmes. Delaware-based…
Bristol Myers Squibb (BMS) has announced that the US Food and Drug Administration (FDA) has given approval to label updates…
Porton Advanced Solutions and EVA Pharma have signed a memorandum of understanding (MoU) to enhance the development and manufacturing capabilities…
Fresh off a regulatory victory for a new HIV product, Gilead is shifting focus to the oncology space – signing…
Revolution Medicines has partnered Royalty Pharma for $2bn in flexible funding to support the independent worldwide development and commercialisation strategy…
The US Food and Drug Administration (FDA) has approved AstraZeneca and Daiichi Sankyo's Datroway (Datopotamab deruxtecan) for adults with locally…
Health Canada has granted a notice of compliance for Novartis Canada’s Kisqali (ribociclib tablets) plus an aromatase inhibitor for the…
The government of New South Wales (NSW), Australia, has announced an investment of A$20.7m ($13.39m) in access to life-changing therapies…
Orion Corporation has broadened its partnership with Glykos, focusing on the development of antibody-drug conjugates (ADCs). Under the research partnership…
NextCure has entered a strategic partnership with Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group, to develop SIM0505, a new…